Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Oncol ; 39(2): 117-120, 2017 Jul.
Article in English | MEDLINE | ID: mdl-29483499

ABSTRACT

The aim of present study was to investigate an antitumor efficacy of multiple-field interstitial photodynamic therapy (iPDT) in vivo. MATERIALS AND METHODS: The study was performed on 15 white random-bred rats with subcutaneously transplanted cholangiocellular carcinoma RS-1. Chlorine-based photosensitizer (PS) Ce6CPPPS was administered via single injection at a dose of 2.5 mg/kg into the animal's caudal vein. Photoirradiation (PI) of tumors was carried out 3 h after PS administration using 7 optical fibers SMA-905 with diode laser with 660 ± 5 nm wavelength at exposure doses of 150 and 300 J/cm² with 0.21 W/cm² fluency rate. The total power density was 360 mW and treatment time was 12 and 24 min. Antitumor efficacy of iPDT was assessed by evaluation of necrosis areas and depth of necrosis in experimental tumors. RESULTS: The results have shown that interstitial PI with multi-field low power density enhanced the antitumor effect of PDT in the RS-1 model. Necrosis areas in tumor tissues after PI with exposure doses 150 and 300 J/cm2 24 h and 96 h after treatment were 83.78 ± 4.25 and 100% (p = 0.00074); 56.79 ± 3.24 and 95.46 ± 1.64% (p < 0.00001), respectively. CONCLUSION: An analysis of the literature data and the results obtained in this study evidence on high effectiveness of the method of multiple-field.


Subject(s)
Bile Duct Neoplasms/pathology , Cholangiocarcinoma/pathology , Photochemotherapy , Animals , Bile Duct Neoplasms/metabolism , Bile Duct Neoplasms/therapy , Cell Line, Tumor , Cholangiocarcinoma/metabolism , Cholangiocarcinoma/therapy , Disease Models, Animal , Light , Necrosis/pathology , Necrosis/therapy , Photochemotherapy/methods , Photosensitizing Agents/pharmacology , Rats , Xenograft Model Antitumor Assays
2.
Exp Oncol ; 36(2): 85-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24980761

ABSTRACT

OBJECTIVE: Investigating the distinctions pharmacokinetics of chlorin e6 conjugated with polyvinyl pyrrolidone photosensitizer (Ce6CPPPS)in healthy and tumor tissues of rat brain and evaluating the antitumor efficacy of combination treatment for C6 rat glioma including photodynamic (PDT) and antiangiogenic therapy (AAT). MATERIALS AND METHODS: The study was performed on 50 white random-bred rats in subcutaneous and intracranial models of C6 glioma. Photosensitizer (PS) Ce6CPPPS single injection at a dose of 2.5 mg/kg was made into the animal's caudal vein. The PS accumulation level in brain tissues and C6 rat glioma was measured with spectral fluorescence technique using LESA-01-Biospek spectrum analyser (Russian Federation, Moscow; λ = 632.8 nm). Photoirradiation of intracranial and subcutaneous C6 glioma was carried out with a light exposure dose of 50 J/cm(2) (IMAF-Axicon, Republic of Belarus; λ = 661 nm). AAT drug bevacizumab, single injection was made intravenously at a dose of 10 mg/kg 24 h after tumor photoirradiation. The criteria for efficacy evaluation were mean survival time (MST) and median survival of the animals in the study group vs the control and the -percentage of tumor necrosis areas induced by the above-mentioned treatment. RESULTS: The optimal time for photoirradiation of intracranial C6 glioma is 0.5 h after Ce6CPPPS injection. The combination therapy group demonstrated a statistically significant MST increase (38.4 ± 4.39 days) compared with the PDT group (29.2 ± 3.5 days) (p = 0.02) and the AAT group (27.1 ± 2.74 days) (p = 0.02). Necrosis areas in tumor tissue were as follows: the intact control - 10.0 ± 2.55%, PDT - 54.87 ± 6.95% (p = 0.003), AAT - 57.83 ± 6.53% (p = 0.003) and combination therapy - 89.43 ± 5.57% (p = 0.001). CONCLUSIONS: This paper is the first report about feasibility of efficient use of PDT with a PS of chlorin series and AAT with bevacizumab for the treatment of brain tumors in experimental models.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/drug therapy , Glioma/diagnosis , Glioma/drug therapy , Luminescent Measurements/methods , Photochemotherapy , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/pharmacology , Animals , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/pharmacology , Bevacizumab , Brain/pathology , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Cell Line, Tumor , Disease Models, Animal , Glioma/mortality , Glioma/pathology , Photosensitizing Agents/administration & dosage , Photosensitizing Agents/pharmacology , Rats , Tumor Burden
SELECTION OF CITATIONS
SEARCH DETAIL